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Animal models constitute valuable tools for investigating the pathogenesis of cancer as
well as for preclinical testing of novel therapeutics approaches. However, the pathogenic
mechanisms of pituitary-tumor formation remain poorly understood, particularly in sporadic
adenomas, thus, making it a challenge to model pituitary tumors in mice. Nevertheless,
genetically engineered mouse models (GEMMs) of pituitary tumors have provided impor-
tant insight into pituitary tumor biology. In this paper, we review various GEMMs of
pituitary tumors, highlighting their contributions and limitations, and discuss opportunities
for research in the field.
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INTRODUCTION
Pituitary adenomas occur in 10–15% of the general population
as determined by autopsy studies (1, 2). The vast majority are
pituitary incidentalomas with no apparent clinical manifestations.
However, clinically significant pituitary tumors are associated
with significant morbidity and decreased quality of life. Pitu-
itary adenomas may cause symptoms due to abnormal hormone
secretion, mass effect, or both. About 50% of pituitary adenomas
are prolactinomas that secrete prolactin and cause galactorrhea
and hypogonadism. GH-producing somatotropinomas, that cause
gigantism and acromegaly, and ACTH-producing corticotropino-
mas that cause Cushing disease constitute 10 and 5% of pituitary
adenomas, respectively. TSH-producing thyrotroph tumors are
rare (less that 1%). Clinically non-functioning pituitary adeno-
mas (NFPA) that do not secrete hormones represent about 30%
of pituitary adenomas (3, 4).
Pituitary adenomas are usually benign. However, a significant
number of pituitary adenomas show an aggressive behavior, with
local invasion, increased risk of recurrence after surgery and lack
of therapeutic response (5, 6). Malignant pituitary carcinomas are
very rare, comprising only 0.2% of all pituitary tumors (7). Non-
endocrine tumors can also be found in the pituitary including
craniopharyngiomas and blastomas that arise from embryonic
remnants of the pituitary (8, 9). Currently available treatment
options for pituitary adenomas include drug therapy (mainly
dopamine-agonist and somatostatin analogs), surgery, and radio-
therapy. However, the currently available therapies fail to control
the disease in a significant number of patients emphasizing the
need to develop novel therapeutic approaches.
The rarity of pituitary tumors, difficulty to obtain biopsy
samples, and lack of human pituitary cell lines pose a sig-
nificant challenge to pituitary-tumor researchers. Animal mod-
els constitute valuable tools for investigating the pathogenesis
of pituitary tumors as well as for preclinical testing of novel
therapeutics approaches. There are a variety of animal mod-
els of pituitary tumors including spontaneous tumors, subcuta-
neous cell implantation, and genetically engineered mouse models
(GEMMs) (transgenic and knockout mice) and each model has its
advantages and limitations. In this review, we focus on GEMMs of
pituitary tumors (Table 1), highlighting their contributions and
limitations, and discuss opportunities for research in the field.
MOLECULAR PATHOGENESIS OF PITUITARY TUMORS
Before we discuss the various GEMMs for pituitary tumors, we will
briefly describe the molecular abnormalities in pituitary tumors.
For a more comprehensive view of this topic, the reader is directed
to several excellent reviews (4, 42–44).
The majority of pituitary adenomas are sporadic. However,
approximately 5% of cases arise in the context of familial syn-
dromes (45) and several of the genes involved in these hereditary
adenomas have been identified. Multiple endocrine neoplasia type
1 (MEN1) is an autosomal dominant familial disorder with muta-
tions in the tumor suppressor gene MEN1. The cyclin-dependent
kinase inhibitor 1B (CDKN1B) is associated with a MEN1-like
phenotype now called MEN4. The McCune-Albright syndrome
is a rare disease caused by mutations in the GNAS oncogene that
encodes the guanine nucleotide-binding protein alpha stimulating
activity polypeptide. Inactivating mutations in the PRKAR1A gene
that encodes the protein kinase A regulatory subunit-1-alpha are
associated with the neoplasia syndrome Carney complex. Famil-
ial isolated pituitary adenoma (FIPA) is a rare syndrome defined
as familial presentation of pituitary adenomas in the absence of
evidence for MEN1 and Carney complex (45). Around 15–40%
of FIPA patients harbor germline mutations in the aryl hydrocar-
bon receptor interacting protein gene (AIP) gene. More recently,
it has been suggested that mutations in succinate dehydrogenase
genes can predispose to pituitary tumors although the evidence is
limited to a single kindred of patients (46).
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Table 1 | Summary of GEMMs for pituitary tumors.
Model type Genetic modification Type of tumor Tumor latency
(months)
Reference
TRANSGENIC
PyLT Polyoma large T antigen
overexpression
Corticotropinoma 9 Helseth et al. (10)
POMC-SV40 large T antigen SV40 large T antigen
overexpression (POMC
promoter)
Intermediate lobe 2–3 Low et al. (11)
AVP-SV40 large T antigen SV40 large T antigen
overexpression (AVP promoter)
GH-producing adenomas – Stefaneanu et al. (12)
FSHβ-SV40 large T antigen SV40 large T antigen
overexpression (FSHβ promoter)
Null cell adenomas 9 Kumar et al. (13)
hGRHH GHRH overexpression Somatotrophs and
mammosomatotrophs
10–24 Asa et al. (14)
PRL-TGFα TGFα overexpression Prolactinomas 12 McAndrew et al. (15)
PRL-ptd-FGFR4 Overexpression of N-terminally
truncated isoform of FGFR4
Prolactinomas 11 Ezzat et al. (16)
αGSU-PTTG1 PTTG1 overexpression Gonadotroph hyperplasia Donangelo et al. (17)
CMV-HMGA1 HMGA1 overexpression Mixed growth hormone/prolactin
adenomas
16 (female)
22 (male)
Fedele et al. (18)
CMV-HMGA2 HMGA2 overexpression Somatotrophs, lactotrophs and
mammosomatotrophs
6 (female)
18 (male)
Fedele et al. (19)
CONVENTIONAL KNOCK OUT
Men1 heterozygous Men1 inactivation Prolactinomas 16 Crabtree et al. (20)
Men1 heterozygous Men1 inactivation Prolactinomas, NFPA >9 Loffler et al. (21)
Men1 heterozygous Men1 inactivation Prolactinomas, GH-producing
adenomas
>13 Bertolino et al. (22)
Men1 heterozygous Men1 inactivation Mammosomatotrophs (90%).
ACTH-producing intermediate
lobe (10%)
12 Harding et al. (23)
AIP heterozygous AIP inactivation GH-producing adenomas (90%),
prolactinomas
6 Raitila et al. (24)
Drd2 homozygous Drd2 inactivation Prolactinomas >12 (only
females)
Kelly et al. (25), Asa et al.
(26)
Prl homozygous Prl inactivation Prolactinomas 8 Cruz-Soto et al. (27)
Prlr homozygous Prl receptor inactivation Prolactinomas 14 Schuff et al. (28)
Rb heterozygous Rb inactivation ACTH-producing intermediate
lobe
12 Jacks et al. (29)
p27Kip1 homozygous p27Kip1 inactivation Intermediate lobe 12 Kiyokawa et al. (30);
Nakayama et al. (31)
p18Ink4c homozygous p18Ink4c inactivation Intermediate and anterior lobe 12 Franklin et al. (32)
Compound p18Ink4c
p27Kip1homozygous
Double p18Ink4c and p27Kip1
inactivation
Intermediate and anterior lobe 3 Franklin et al. (32)
(Continued)
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Table 1 | Continued
.
Model type Genetic modification Type of tumor Tumor latency
(months)
Reference
Cdk4R24C/R24C mutant mice Mutation rendering the Cdk4
protein insensitive to INK4
inhibitors
Anterior lobe 15 Sotillo et al. (33)
Compound Cdk4R24C/R24C
p27Kip1 homozygous mutant
mice
Mutation rendering the Cdk4
protein insensitive to INK4
inhibitors and and p27Kip1
inactivation
Poorly differentiated adenomas 2 Sotillo et al. (34)
CONDITIONAL KNOCK OUT
rGhrhr -Cre PRKAR1A Pituitary-specific (somatotrophs,
lactotrophs, and thyrotrophs)
PRKAR1A inactivation
Somatotrophs, lactotrophs, and
thyrotrophs
18 Yin et al. (35)
POMC-specific Rb
heterozygous
Rb inactivation in
POMC-expressing cells
Intermediate lobe 9 Vooijs et al. (36)
POMC-specific Rb
homozygous
Rb inactivation in
POMC-expressing cells
Intermediate lobe 3 Vooijs et al. (36)
POMC-specific Rb
homozygous
Rb inactivation in
POMC-expressing cells
Not reported 6 Vooijs et al. (37)
Ins-Cre Men1 Men1 homozygous inactivation
in pituitary due to ectopic Cre
expression
Prolactinomas 9 Biondi et al. (38)
GFAP-Cre Bmi1 Bmi1 homozygous
pituitary-specific inactivation
Intermediate lobe >12 Westerman et al. (39)
Hesx1-Cre;Ctnnb1lox(ex3)+
Sox2-CreERT2;Ctnnb1lox(ex3)+
Pituitary-specific overexpression
of constitutively active form of
β-catenin
Adamantinomatous,
craniopharyngioma
3–6 Gaston-Massuet et al. (40)
Andoniadou et al. (41)
Pituitary adenomas are thought to be of monoclonal origin
according to early studies (47, 48). Despite extensive research on
pituitary tumors in the last decade, the molecular mechanisms
underlying tumorigenesis in sporadic pituitary tumors remain
unclear. There is little evidence to date that the mutations associ-
ated to familial pituitary adenomas are involved in most sporadic
pituitary adenomas. The GNAS gene is the only gene in which
mutations have been found in a significant proportion of spo-
radic pituitary adenomas (30–40% of GH-producing adenomas)
although the oncogenic role of such mutations is still unclear
(49, 50). Similarly, mutations in classical oncogenes and tumor
suppressor such genes TP53 and MYC are only rarely observed,
and restricted to aggressive or pituitary carcinomas. However, a
significant number of molecular abnormalities, including cell-
cycle deregulation, overexpression of growth factors, hormonal
overstimulation, epigenetic silenced tumor suppressor genes, and
defective signaling pathways have been found in pituitary adeno-
mas although their causative role in pituitary-tumor formation
remains to be firmly established (4, 42–44).
Cell-cycle deregulation is considered the main pathogenic event
in the formation of pituitary adenomas. It has been estimated
that around 80% of human pituitary adenomas display alter-
ations at least in one cell-cycle regulator (51, 52). These alterations
include overexpression of cyclins (mainly D1, D3, and E), as well
as to downregulation of the cyclin-dependent kinase inhibitor
family (mainly p15Ink4b, p16Ink4a, p18Ink4c, p21Cip1, and p27Kip1)
and pRB expression (53). Cyclin D1 and D3 are overexpressed
particularly in NFPA while cyclin E is overexpressed mainly in
ACTH-producing corticotropinomas. Reduced levels of the INK4
family members of cyclin-dependent kinase inhibitors, p15Ink4b,
p16Ink4a, and p18Ink4c in pituitary adenomas appear to be caused
mainly by promoter hypermethylation (54–57). Decreased lev-
els of p27Kip1 are common in pituitary carcinomas and ACTH-
producing corticotropinomas (58, 59). p21Cip1 is also downreg-
ulated in NFPAs but, interestingly, appears to be overexpressed
in hormone-secreting pituitary adenomas (60). The retinoblas-
toma tumor suppressor protein (pRb) plays a critical role in G1-S
cell-cycle progression. Loss of pRb expression has been found
in human sporadic pituitary adenomas (particularly in invasive
types) due to loss of heterozygosity or promoter hypermethylation
(61, 62). Pituitary-tumor transforming gene 1 (PTTG1) is a mem-
ber of the securin family and plays an important role in mitosis by
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controlling sister chromatid separation. PTTG1 is overexpressed
in nearly all pituitary adenomas, especially in invasive hormone-
secreting pituitary tumors (63). However, its oncogenic role in
human pituitary tumorigenesis is unclear. HMGA2 is another
oncogene that has been found to be overexpressed in pituitary
adenomas (64). More recently, increased expression of HMGA1 in
human pituitary adenomas has also been described. This increased
expression correlates with tumor invasiveness and proliferation
(65). HMGA1 and 2 are members of the high mobility group A
(HMGA) protein family, non-histone chromatin binding proteins
that act as modulators of cellular processes such as transcription,
replication, and recombination. HMGA proteins appear to induce
the development of pituitary adenomas through mechanisms
involving cell-cycle deregulation.
Several alterations in the expression of growth factors and/or
growth factor receptors are frequently observed in pituitary ade-
nomas, including TGFα, EGF, VEGF, and FGF. FGF is one of the
best-studied growth factor family in pituitary tumors. FGF-4 is
upregulated in pituitary adenomas and its expression correlates
with tumor invasiveness. Expression of a N-terminally truncated
isoform of FGFR4 (ptd FGFR4) has been found in pituitary ade-
nomas but not in normal pituitary (16). Experimental evidence
suggests a tumorigenic role for this isoform in pituitary (16). In
contrast, the FGFR2-IIIb isoform appears to be downregulated in
pituitary tumors, due to epigenetic modifications (66).
Deregulation of hypothalamic and pituitary feedback mecha-
nisms have long been proposed to participate in pituitary tumori-
genesis based on the defects in hormonal signaling observed in
pituitary adenomas, mainly in GH- and ACTH-producing ade-
nomas. Thus, increased GHRH expression has been found in
aggressive somatotropinomas (67) and pituitary hyperplasia have
been observed in patients with endocrine carcinomas ectopically
secreting GHRH (68). An inactivating mutation of the GH recep-
tor has also been described in somatotropinomas (69). Differential
expression of vasopressin receptors has been reported in ACTH-
producing pituitary tumors (70). Also, mutations in the gluco-
corticoid receptor that reduce glucocorticoid inhibition have been
described in corticotroph tumors (71). In prolactinomas, dimin-
ished D2 dopamine receptor activity appears to mediate resistance
to dopamine-inhibited hormone secretion (72).
Finally, various signaling pathways have been recently impli-
cated in pituitary tumorigenesis. Akt is overexpressed in pituitary
adenomas, particularly NFPAs (73) and mutations and ampli-
fications of the phosphoinositide 3-kinase PIK3CA gene have
been found in pituitary adenomas (74) suggesting a role for the
PI3K/AKT in pituitary adenoma formation. Activation of the
Raf/MEK/ERK signaling pathway has also been observed in pitu-
itary adenomas, as demonstrated by the finding that B-Raf is
overexpressed, and its downstream effectors MEK1/2 and ERK1/2
overactivated, in pituitary adenomas (75, 76). Increased levels
of the hypoxia-inducible factor HIF1α transcription factor have
been found in pituitary tumors but not in the normal pituitary
(77, 78). Decreased expression of inhibitors of the canonical Wnt
pathway has been reported in pituitary adenomas (79). Although
these results might suggest the WNT pathway is overactivated in
pituitary adenomas, nuclear accumulation of β-catenin was not
observed (79). However, activating mutations have been found
in the CTNNB1 gene that encodes β-catenin in around 70% of
the pediatric form of human craniopharyngioma (adamantino-
matous) (80, 81), a pituitary tumor of embryonic origin. Further
mechanistic studies are necessary to fully understand the role of
these signaling pathways in pituitary-tumor formation.
GENETICALLY ENGINEERED MOUSE MODELS OF PITUITARY
TUMORS
TRANSGENIC MICE
A common strategy to generate mouse models of cancer is to
express viral oncoproteins in the cell/tissue of interest. These
animal models based on viral oncogene overexpression provide
limited insight into the mechanisms underlying pituitary-tumor
formation. However, they can be considered useful tools to study
various aspects of pituitary adenomas such as hormone secretion
regulation and pathophysiology of hormone excess.
One of the first mouse models of pituitary tumors was gener-
ated by expressing the (PyLT) under the control of the polyoma
early region promotor. These transgenic mice developed ACTH-
producing microadenomas at 9 months of age, large adenomas
at 13–16 months of age, and display features of Cushing’s syn-
drome (10). Several mouse strains generated using oncogenic
viruses were generated specifically targeting the pituitary. Thus,
expression of the simian virus 40 (SV40) large T antigen under
the control of the proopiomelanocortin (POMC) gene promoter
induced the formation of pituitary tumors arising from the inter-
mediate lobe. These tumor cells expressed POMC peptides, but not
other pituitary hormones (11). SV40 large T antigen overexpres-
sion using another promoter, the arginine vasopressin (AVP) gene
promoter, also resulted in pituitary tumors although these tumors
were composed of undifferentiated somatotroph cells (12). Trans-
genic mice carrying a temperature-sensitive mutant of simian
virus 40 T antigen driven by regulatory elements of the beta sub-
unit of human follicle-stimulating hormone (FSHβ) gene develop
pituitary-tumors reminiscent of human null cell adenomas (13).
As mentioned in the previous section, various hypothalamic
hormones and growth factors required for normal pituitary func-
tion and formation are overexpressed in pituitary adenomas.
Transgenic approaches allow the overexpression of these hor-
mones and factors specifically in the pituitary to evaluate their role
in pituitary tumorigenesis. Overexpression of the GH-releasing
hormone (GHRH) gene in mice results in hyperplasia of pituitary
somatotrophs, lactotrophs, and mammosomatotrophs (cells pro-
ducing both GH and PRL) by 8 months of age that leads to mixed
GH and prolactin secreting pituitary adenomas by 10–24 months
of age (14). These results indicate that GHRH might promote
proliferation of transformed pituitary cells. However, the extended
tumor latency period suggests the requirement for additional mol-
ecular alterations in the formation of pituitary tumors in these
mice. A transgenic mouse model was generated in which TGFα
was specifically overexpressed in the pituitary lactotrophs using
the prolactin promoter (15). These transgenic mice developed lac-
totroph hyperplasia at 6 months of age and prolactin-producing
pituitary adenomas with high penetrance by 12 months of age.
Pituitary lactotroph-specific overexpression of the N-terminally
truncated isoform of FGFR4 (ptd-FGFR4), but not the wild-type
FGFR4, in mice leads to the development of tumors reminiscent
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of human prolactinomas (16). Interestingly, ptd-FGFR4 overex-
pression causes pituitary adenoma formation without preceding
hyperplasia. The mechanism by which ptd-FGFR4 might facil-
itate pituitary cell transformation appears to involve alterations
in neural cell-adhesion molecule/N-cadherin signaling that lead
to diminished cell-adhesion (82). The oncogenic role of PTTG1
and HMGA2, two oncogenes previously suggested to play a rel-
evant role in human pituitary adenoma formation, has been
analyzed in transgenic mice. Targeted PTTG1 overexpression to
gonadotroph cells of the pituitary driven by the alpha-subunit gly-
coprotein (alphaGSU) promoter results in gonadotroph hyperpla-
sia (17). However, only occasional microadenomas were observed.
These observations seem to question the tumorigenic potential of
PTTG1 in pituitary. However, when overexpressing-PTTG1 mice
were crossed with Rb heterozygous mice, which develop pituitary
tumors with high penetrance (see below), increased frequency of
pituitary adenomas was observed. On the contrary, PTTG1 dele-
tion diminishes pituitary-tumor development in Rb heterozygous
mice (83). Taken together, these results obtained from genetically
modified mice indicate that PTTG1 facilitates pituitary adenoma
formation. Transgenic mice expressing high levels of the HMGA2
transgene in all tissues (by using the cytomegalovirus promoter)
developed mixed growth hormone/prolactin cell pituitary adeno-
mas with high penetrance (85% of female animals) by 6 months of
age (19). Of note, transgenic males developed pituitary adenomas
with a lower penetrance (40%) and a longer latency period (about
18 months). Interestingly, HMGA1 overexpression also leads to
the development of pituitary adenomas secreting prolactin and
GH (18). Subsequent studies performed in these transgenic mice
have shown that HMGA proteins mediate the formation of these
tumors through a mechanism that involves the Rb/E2F1 pathway,
thus further supporting a critical role of this pathway in pituitary
tumorigenesis (84).
Altogether, transgenic mice overexpressing proteins in the pitu-
itary have provided important insights into pituitary tumorigen-
esis. One of the major limitations of these mouse models is the
regulation of the expression of the transgene that ideally should
be limited to adult stages, thus mimicking the human situation.
CONVENTIONAL KNOCKOUT MODELS
The use of conventional or whole-body knockout mouse mod-
els provides a different approach for analyzing the function of
important genes in pituitary tumorigenesis. Thus, conventional
knockout mice are a crucial tool to analyze the role of tumor
suppressor genes in pituitary tumorigenesis. Conventional knock-
out mice have been generated to assess the direct effect of several
genes linked to familial pituitary tumors such as MEN1, CDKN1B,
and AIP in pituitary-tumor development. Four different Men1
knockout mouse strains have been generated (20–23). Homozy-
gousMen1mice are embryonic lethal due to defects in craniofacial
development but heterozygous Men1 mice are viable and have
been extensively analyzed for tumor formation. In general, all
these Men1 heterozygous mouse models correlate closely with the
human MEN1 phenotype regarding tumor incidence and spec-
trum. These mice develop tumors of various endocrine tissues,
including pancreatic islet cell tumors, pituitary and parathyroid
adenoma, and adrenocortical tumors. Loss of heterozygosity and
menin expression was demonstrated in the tumors, consistent
with a tumor suppressor role for the Men1 gene. Furthermore,
a higher occurrence of anterior pituitary tumors is observed in
female Men1 heterozygous mice, similar to what it is observed in
MEN1 patients. However, the different Men1 mouse models also
show slight phenotypic differences including the type of pituitary
adenomas developed. Thus, only prolactin producing adenomas
were observed in the Men1 mouse model generated by Crabtree
et al. (20) while prolactinomas and non-secreting adenomas were
found in the model generated by Loffler et al. (21). Bertolino et al.
(22) reported the formation of prolactinomas and GH-secreting
tumors. Finally, Harding et al. (23) reported that the majority the
pituitary tumors originated from the pars distalis and contained
both prolactin and GH while around 10% of the tumors origi-
nated from the pars intermedia and contained ACTH. The reason
for these differences in pituitary-tumor formation is unclear but it
might be related to the types of Men1 mutations (different exons
were targeted) and/or differences in genetic background.
Recently, a conventional knockout mouse deficient in the AIP, a
gene linked to familial isolated pituitary adenoma (FIPA), and iso-
lated familial somatotropinomas have been generated. Homozy-
gous knockout Aip mice died during embryogenesis, likely due to
cardiovascular abnormalities (24). Heterozygous Aip mice were
highly prone to pituitary adenomas, developing tumors as early as
at 6 months of age (24). Thus, unlike in humans in whom AIP-
associated tumors often develop in childhood or early adulthood
(85), heterozygous Aip mice develop adenomas in adulthood.
Another major difference between the Aip mouse model and the
human disease is the complete penetrance of pituitary tumors
in the Aip mouse model (at 15 months of age). The majority of
adenomas found in the Aip mouse model were somatotropino-
mas, although mixed GH/prolactin, prolactinomas, and ACTH-
corticotropinomas were also found. Biallelic inactivation of AIP
was demonstrated in these tumors.
Analysis of conventional knockout mice has also been use-
ful to analyze the effect of disruption of feedback signaling in
pituitary-tumor pathogenesis. Thus, analysis of dopamine recep-
tor 2 (Drd2) knockout mice indicates that functional inactivation
of this receptor might contribute to the formation of pituitary
adenomas, namely prolactinomas. Female Drd2 knockout mice
develop massive lactotroph hyperplasia by 12 months of age and
invasive prolactinomas at older ages. (25, 26). Male Drd2 knock-
out mice develop microadenomas in the absence of hyperplasia.
The effects of disrupted prolactin feedback on pituitary tumori-
genesis have been demonstrated in knockout mice deficient for
prolactin and prolactin receptor (Prlr). Prolactin knockout mice
develop lactotroph hyperplasia by 6 weeks of age and prolactino-
mas by 8 months of age (27). Inactivation of Prlr also results in
lactotroph hyperplasia and formation of invasive adenomas (28).
Studies performed in mice with targeted disruption of cell-cycle
regulators collectively support the notion that cell-cycle dysregu-
lation is central in pituitary tumorigenesis (51). Mice heterozy-
gous for Rb develop ACTH-producing aggressive tumors arising
from the intermediate lobe of the pituitary with high penetrance
by 12 months of age (29). Subsequent studies have shown that
pituitary-tumor incidence and histological type in Rb heterozy-
gous mice is dependent on the mouse strain suggesting an effect
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of modifier genes in pituitary adenoma formation (86). Homozy-
gous mice deficient for the cyclin-dependent kinase inhibitors
p27Kip1 and p18Ink4c also develop pituitary adenomas. Homozy-
gous p27Kip1mice develop tumors from the intermediate lobe by
12 months of age (30, 31) while p18Ink4c mice develop pituitary
adenomas in both the intermediate and anterior lobes (32). Inac-
tivation of other cyclin-dependent kinase inhibitors that are down-
regulated in human pituitary adenomas, such as p21Cip1, p15Ink4b,
and p16Ink4a, does not result in pituitary tumors in mice. The
generation of mice with combined inactivation of different cyclin-
dependent kinase inhibitors has revealed a cooperation of these
cyclin-dependent kinase inhibitors in pituitary-tumor formation.
Thus, deletion of p21Cip1, p27Kip1, or p16Ink4a in combination
with loss of p18Ink4c results in increased incidence and decreased
latency of pituitary tumors compared to single mutants (32, 87,
88). Of note, double p18Ink4c p27Kip1 mutant mice appear to die
by 3 months of age due to pituitary adenomas (32). The relevance
of INK4 family proteins in pituitary adenoma formation is fur-
ther supported by the analysis of knock-in mice, which express
a CDK4 variant with a mutation that renders the Cdk4 protein
insensitive to INK4 inhibitors (Cdk4R24C/R24C mutant mice) (33,
89). These Cdk4R24C/R24C knock-in mice develop multiple tumors
including pituitary tumors (25% of penetrance) arising in the
anterior pituitary by 15 months of age. A dramatic cooperation in
pituitary-tumor formation is observed in double Cdk4R24C/R24C
p27Kip1 mutant mice, which develop poorly differentiated pitu-
itary tumors that kill these mutant mice in 8–10 weeks of age (34).
Cooperation between cyclin-dependent kinase inhibitors and Rb
in pituitary-tumor formation has also been observed. Inactivation
of p27Kip1 and p21Cip1inRb heterozygous mice results in decreased
latency of pituitary tumors (90, 91). Similarly, loss of p16Ink4a
strongly accelerates intermediate lobe pituitary tumorigenesis in
Rb heterozygous mice (92).
The usefulness of conventional knockout mice as models for
evaluating therapeutic agents is highlighted by studies performed
with bromocriptine, a dopamine agonist used to treat prolactin-
omas. Thus, it has been reported that bromocriptine decreases
prolactin serum levels in Prlr mutant mice harboring tumors (28)
and reduces tumor cell proliferation in p27Kip1 deficient mice (93).
Bromocriptine does not affect prolactin levels in Drd2 knockout
mice, as expected from the absence of the dopamine receptor 2
(28) and thus, these mice can be considered a useful model for
dopamine-resistant prolactinomas. The effectiveness of antiangio-
genic treatments in dopamine-resistant prolactinomas has been
analyzed in Drd2 knockout mice. Anti-VEGF strategies resulted
in prolactin inhibition and decreased tumor cell proliferation in
these mice (94).
The mouse models discussed above illustrate how conventional
knockout mice help to elucidate the causal role of genes that were
predicted to be important for human pituitary tumorigenesis.
These conventional knockout mice can also be useful as preclinical
models for testing of therapeutic agents.
CONDITIONAL KNOCKOUT MODELS
The development of conditional gene targeting has allowed to
overcome some of the limitations of conventional knockout mice
such as potential embryonic lethality or complications due to
systemic effects of gene inactivation. The most widely used condi-
tional system is based on the Cre-loxP technology. Combinations
of Cre-loxP systems, specific promoters, and inducible systems
(i.e., tamoxifen) allow tissue- and time-specific inactivation of
the gene of interest. The number of pituitary-specific Cre lines
available is rapidly increasing (35, 95–102). The generation of
pituitary cell-specific Cre transgenic lines has been instrumen-
tal in advancing our understanding of pituitary cell function and
cell lineages. However, to date, relatively few studies have exploited
these Cre lines to evaluate the role of genes of interest in pituitary
tumorigenesis.
To explore the role of inactivation of the Carney complex gene
PRKAR1A on pituitary tumorigenesis, a pituitary-specific knock-
out of this gene was generated by crossing mice with conditional
alleles of Prkar1a with a mouse line expressing the Cre recombi-
nase in pituitary cells using the GHRH receptor promoter (rGhrhr-
Cre line) (35). This promoter, drives Cre-mediated recombination
in pituitary cells of the Pit1 lineage, including somatotrophs, lac-
totrophs, and thyrotrophs. Pituitary-specific Prkar1a knockout
mice exhibited a moderate increased frequency of pituitary adeno-
mas, although not until advanced age (18 months). These tumors
were composed of cells that expressed GH, prolactin, and TSH.
Using a different conditional system based on the Flp recombinase,
specific inactivation of Rb in pro-opiomelanocortin-expressing
cells has been achieved. Mice in which only an allele of Rb was
conditionally inactivated in the pituitary displayed atypical lesions
in the intermediate lobe of the pituitary by 6–12 weeks of age
that resulted in adenoma formation as the mice aged. Accel-
erated adenoma formation was observed in mice homozygous
for the conditional alleles of Rb. These mice developed pituitary
adenomas with 100% incidence as early as 12 weeks of age and
succumbed to these adenomas by 20 weeks of age (36). The ade-
nomas originated from the intermediate lobe melanotrophs and
were indistinguishable from the adenomas observed in conven-
tional Rb heterozygous mice. Pituitary-specific inactivation of Rb
has also been achieved using a mouse strain in which Cre expres-
sion is under the control of the POMC gene promoter. These mice
developed pituitary adenomas with 100% incidence after a rela-
tively short median latency (around 6 months) (37). However, no
histological characterization of the adenomas was reported. Inter-
estingly, in this study pituitary adenoma formation in vivo was
monitored by crossing conditional Rb knockout mice with trans-
genic mice that express luciferase under the control of the POMC
promoter detecting tumor growth as early as 8 weeks of age.
Pituitary adenomas have been also reported in conditional
mouse models using non-pituitary-specific Cre lines. Thus, condi-
tional inactivation of the MEN1 gene using a mouse line in which
Cre expression was driven by the insulin promoter resulted in the
formation of pituitary adenomas (in addition to islet tumors) by
12 months of age (38). All pituitary adenomas were derived from
the pars distalis, as determined by expression of prolactin. The
formation of pituitary adenomas in these mice was attributed to
aberrant Cre expression in the pituitary. Conditional activation
of the polycomb ring finger oncogene using a GFAP-Cre that dri-
ves expression in neural and glial lineages developed intermediate
and anterior lobe pituitary tumors positive for ACTH and beta-
endorphin although with incomplete penetrance and long latency
Frontiers in Oncology | Cancer Genetics August 2014 | Volume 4 | Article 203 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cano et al. Mouse models of pituitary tumors
period (1 year) (39). Consistent with these results, Cre expres-
sion in the GFAP-Cre line was observed in the pituitary. However,
it is unclear whether this Cre activity in the pituitary represents
endogenous GFAP expression or ectopic expression of the Cre
transgene.
The usefulness of conditional knockout mouse models in the
study of pituitary-tumor formation is perhaps best illustrated
by two recent studies that analyzed the role of Wnt/β-catenin
signaling pathway in pituitary tumorigenesis. Expression of a
degradation-resistant mutant form of β-catenin in embryonic
pituitary using the Hesx1-Cre line was shown to cause the for-
mation of tumors resembling human adamantinomatous cran-
iopharyngioma (ACP) (40). ACP is a type of pediatric non-
hormone-producing tumor derived from pituitary embryonic
tissue associated with significant morbidity and mortality (8).
Interestingly, expression of mutant β-catenin in differentiated cells
in the embryonic or adult pituitary using specific Cre lines (Gh-
Cre,Prl-Cre,and Pit1-Cre) did not give rise to tumors (40). Further
studies from the same group using specific a tamoxifen-inducible
Cre line demonstrated that activation of mutant β-catenin in
Sox2-expressing adult pituitary stem cells also result in the forma-
tion of ACP-like tumors (41). The molecular characterization of
the tumors formed in these mouse models of ACP have uncov-
ered a number of genes and pathways potentially involved in
the formation of ACP including the SHH, BMP, and FGF path-
ways (103). These findings have been validated in human ACP
(103) in what is an excellent example of how genetic studies
in mice harboring conditional mutations, in addition to pro-
viding mechanistic insight into pituitary tumorigenesis, can lead
to the generation of new animal models for modeling human
disease.
CONCLUSION AND FUTURE DIRECTIONS
Although current GEMMs of pituitary tumors exhibit, to some
degree, biochemical and molecular features of pituitary adenomas,
no current mouse model exists that fully recapitulates pituitary-
tumor formation. The ideal mouse model of cancer faithfully
recapitulates the genetic lesions found in human disease. How-
ever, the primary genetic defect/s for pituitary tumorigenesis
remains unclear. Furthermore, the pathogenic mechanisms for
tumor formation may be specific for the different pituitary ade-
noma subtypes thus, making it a challenge to model pituitary
tumors in mice. Despite these limitations, current GEMMs of
pituitary tumors have provided important insight into pituitary-
tumor biology. Transgenic and knockout mice have proven to be a
powerful tool to examine the role of genes predicted to be impor-
tant for human pituitary tumorigenesis. Thus, the use of knockout
mice has validated the putative oncogenic role of genes linked
to familial pituitary adenomas such as MEN1 and AIP. Also, the
analysis of knockout mice deficient in cell-cycle regulators such as
Rb and cyclin-dependent kinase inhibitors have provided evidence
that cell-cycle deregulation may be a critical event in pituitary
tumorigenesis. As the number of genes found to be deregulated
in pituitary adenomas continues to increase, we can expect to see
the generation of new mouse models with deletion or overexpres-
sion of those genes in the near future. The recent generation of
pituitary-specific Cre-expressing mouse strains will certainly have
a significant impact in this area since it will permit the analysis of
genes in a cell type-specific and temporal fashion thus circumvent-
ing problems often associated to conventional knock out mice such
as embryonic lethality. Nevertheless, a more detailed characteri-
zation of current GEMMs for pituitary tumors may still provide
additional valuable insight into pituitary tumorigenesis. For exam-
ple, in the vast majority of GEMMs of pituitary tumor, adenomas
arise after a long latency period suggesting the requirement of
additional genetic events. The identification of such events might
uncover underlying mechanisms of adenoma formation. Further
studies in existing GEMMs may also help to address important spe-
cific questions on pituitary tumors that cannot be easily addressed
in human such as the cell of origin for pituitary adenomas, inter-
action between tumor cells and tumor microenvironment, and
mechanisms underlying adenoma invasiveness.
Ultimately, the goal of generating faithful GEMMs of cancer is
to evaluate therapeutic strategies. However, there is a scarcity of
studies evaluating current available therapies for pituitary tumors
in GEMMs. Such studies are fundamental to determine the utility
of GEMMs of pituitary tumors for preclinical testing of new ther-
apeutic drugs. In this regard, the use of non-invasive imaging to
assess monitoring of tumor growth and response to therapy can
enhance the utility of these mouse models for preclinical testing
as previously shown in Rb conditional knock out mice (37).
As our understanding of the molecular mechanisms involved in
pituitary adenoma formation improves, we can expect the genera-
tion of more sophisticated and diverse GEMMs that will undoubt-
edly facilitate research in pituitary tumorigenesis, the identifica-
tion of biomarkers of tumor aggressiveness and preclinical testing
of novel therapies.
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